TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-6517
Description: Engineered Oncolytic Vaccinia Virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor.
Study: NCT01624467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: 800 mg necitumumab, administered once per week IV
Study: NCT02752425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: Use of ultrasound echography for tongue articulatory visual feedback
Study: NCT02276794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation
Description: After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-thrust manipulation (NTM)
Description: A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
Study: NCT02037204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartilage repair surgery
Description: Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
Study: NCT04443036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: * 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: * 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months
Study: NCT01861613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
Study: NCT04509557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
Study: NCT05455255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
Study: NCT03815760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Subjects will perform sidelying external rotation exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction
Description: Subjects will perform sidelying external rotation exercise
Study: NCT00861094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study: NCT02406339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Neuromuscular Electrical Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Neuromuscular Electrical Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Occlusion
Description: Restriction of sanguine flow to the lower limbs
Study: NCT03465124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser
Description: Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
Study: NCT00881140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone vaginal tablets
Description: Daily use of 10 mg administrated per vagina for 3 months
Study: NCT02823236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Pirfenidone
Description: Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone + Pirfenidone
Description: Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Triamcinolone
Description: Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
Study: NCT02869685

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: radiotherapy
Study: NCT03821480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: Fluconazole capsule 50 mg Manufacturer: West Ryde

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference drug
Description: Fluconazole capsule 50 mg Manufacturer: Amboise
Study: NCT03961893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE first and standard colonoscope
Description: Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard colonoscope first and G-EYE
Description: Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
Study: NCT03694067

Intervention type: OTHER
Intervention: Punch skin biopsy
Description: One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
Study: NCT01942408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat PVI
Description: Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
Study: NCT00711412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Therapy - Capecitabine
Description: Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Therapy - Oxaliplatin
Description: Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy - Capecitabine
Description: Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy - Oxaliplatin
Description: Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
Study: NCT03465124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Cataract Surgery
Description: conventional cataract surgery as control
Study: NCT00174954

Intervention type: PROCEDURE
Intervention: MRI
Description: Subjects underwent MRI to evaluate tophi.
Study: NCT00818688

Intervention type: PROCEDURE
Intervention: compression ultrasonography at 3 months
Description: A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
Study: NCT00711412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Combination Therapy - Radiation
Description: 1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
Study: NCT00090363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 15 mg
Description: 15 mg oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 10 mg
Description: 10mg oral tablet once daily
Study: NCT03963986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STIMUL group
Description: The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
Study: NCT03735316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Description: 5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
Study: NCT00711412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation for response and surgery
Description: Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
Study: NCT02065193

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment
Study: NCT03735316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Bypass
Description: Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary Bypass
Description: Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
Study: NCT00727870

Intervention type: DEVICE
Group type: OTHER
Intervention: Shapes by PolyMem dressing
Description: Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site

Intervention type: DEVICE
Group type: OTHER
Intervention: Shapes by PolyMem Silver Dressing
Description: Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site

Intervention type: DEVICE
Group type: OTHER
Intervention: Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site
Description: Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
Study: NCT03694600

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-analyte blood Test
Description: intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
Study: NCT00952211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP at therapeutic pressure during nighttime
Study: NCT03976557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP CVC
Description: Central venous access with noble metal coated CVC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CVC
Description: Central venous access with standard uncoated CVC
Study: NCT02724280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WLE and then LCI
Description: The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LCI and then WLE
Description: The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
Study: NCT00952211

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP at sub-therapeutic pressure
Description: CPAP delivered at sub-therapeutic pressure at nighttime
Study: NCT00094861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Study: NCT00628342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg Oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral once daily
Study: NCT01770886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UE2343
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT00943410

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
Study: NCT04251741

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adalimumab trough concentration
Description: In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: In the usual care group, switch to subsequent biological is based on secondary randomisation
Study: NCT01840436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUCIPLIQ
Description: MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUCIPLIQ
Description: MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
Study: NCT00441727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Description: Esomeprazole 20 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT04827940

Intervention type: OTHER
Group type: OTHER
Intervention: Progressive relaxation exercise with music
Description: The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise with music
Description: The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.
Study: NCT03066310

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
Study: NCT01111721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project POWER HIV Risk-reduction Intervention
Description: Nine session group-based behavioral intervention for incarcerated female adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NC DOC Standard of Care for STIs
Description: Standard North Carolina Department of Correction intake STI testing and counseling.